Resistance to CD19 Immunotherapy in B-Cell ALL Is Associated with Loss of CD19 and CD22 and an Enhanced Vulnerability to B Cell Receptor Signaling InhibitionSarah Aminov, Amit Verma, R. Alejandro Sica et al.|Blood|2022Cited by 3